| Imbruvica (ibrutinib) / AbbVie, J&J |
ChiCTR2100053513: Prospective, controlled, multicenter real-world clinical study of zanubrutinib versus ibrutinib in maintenance monotherapy for chronic lymphocytic leukemia/small cell lymphoma and mantle cell lymphoma |
|
|
| Recruiting | 4 | 210 | | Zanubrutinib ;Ibrutinib ;Initial maintenance therapy with ibrutinib and then switched to zanubrutinib due to intolerance or voluntary | The Second Affiliated Hospital of Nanchang University; The Second Affiliated Hospital of Nanchang University, self-funded | Chronic lymphocytic leukemia/small cell lymphoma and mantle cell lymphoma | | | | |
NCT03190330: A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion |
|
|
| Completed | 4 | 75 | RoW | Ibrutinib 420 mg, Imbruvica, Ibrutinib 560 mg | Johnson & Johnson Private Limited | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell | 05/23 | 05/23 | | |
ChiCTR2000041420: A randomized, open label, multicenter study of ibotinib monotherapy versus ibotinib combined with nitrogen mustard in the first-line treatment of chronic lymphocytic leukemia / small lymphocytic lymphoma |
|
|
| Recruiting | 4 | 300 | | Ibrutinib monotherapy ;Ibrutinib plus chlorambucil | Ruijin Hospital Shanghai Jiaotong University School of Medicine; Ruijin Hospital Shanghai Jiaotong University School of Medicine, Investigator-sponsored | Chronic lymphocytic leukemia/small lymphocytic lymphoma | | | | |
NCT04042376: A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) |
|
|
| Completed | 4 | 17 | RoW | Ibrutinib, JNJ-54179060, PCI-32765 | Janssen Research & Development, LLC | Waldenstrom Macroglobulinemia | 03/24 | 03/24 | | |
ChiCTR2000038447: Clinical study of ibrutinib combined with pirfenidone in the treatment of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation |
|
|
| Not yet recruiting | 4 | 15 | | Ibutenib and pirfenidone | Sichuan Provincial People's Hospital, Affliated Hospital of University of Electronic Science and Technology of China; Sichuan Provincial People's Hospital, Affliated Hospital of University of Electronic Science and Technology of China, self-raised | bronchiolitis obliterans syndrome | | | | |
| Active, not recruiting | 4 | 297 | Europe, Canada, US, RoW | Ibrutinib | Pharmacyclics Switzerland GmbH, Janssen Biotech, Inc., including Johnson & Johnson | Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor | 05/27 | 05/27 | | |
